Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: <em>Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL)</em>

COLUMBIA, S.C. (September 10, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Atropine Sulfate Injection 1.2 mg/3 mL (0.4 mg/mL). It is the last of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is

Continue reading

Ritedose Launches Critical Care Single-Dose Syringe Product Amid National Shortage: <em>Epinephrine Injection 1 mg/10 mL (0.1 mg/mL)</em>

COLUMBIA, S.C. (August 24, 2021) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Epinephrine Injection 1 mg/10 mL (0.1 mg/mL). It is the 11th of a 12-product, six-month rollout from Ritedose for hospital pharmacies across the country. Ritedose is a

Continue reading

Ritedose Efficiency Innovation Yields Up to 25% Increase in CDMO Production Capability

Engineering for Surge Development Columbia, SC – The Ritedose Corporation, the company born from the inventors of Blow-Fill-Seal (BFS) technology, has implemented engineering innovations that will now allow the country’s leading BFS Contract Development and Manufacturing Organization (CDMO) to increase its production capacity by up to 25% over industry standards.

Continue reading